Investment
Features
FeesSafety
Academy
More
Pluang+

Reckitt Benckiser faces mixed Q3 sales forecasts but retains buy ratings from UBS and Jefferies.

Market News
01 Oct 2026
Proactive Investors
View Source
Neutral
Reckitt Benckiser faces mixed Q3 sales forecasts but retains buy ratings from UBS and Jefferies.

Reckitt Benckiser's third-quarter sales forecasts vary between UBS and Jefferies, though both maintain 'buy' ratings. UBS predicts 3.7% like-for-like sales growth, expecting broad-based improvements and strong emerging market momentum, while Jefferies is more cautious, forecasting 3.5% growth with challenges in US self-care and Chinese vitamins sales. UBS raised its price target to 7,600p, while Jefferies lowered theirs to 5,900p. Both brokers highlight the importance of fourth-quarter performance to meet full-year growth targets.

Reckitt Benckiser's third-quarter sales forecasts show mixed broker views ahead of its update. For readers following Consumer Staples, here is Pluang's market snapshot as of Oct 01, 2026 17:42 WIB: Among 51 priced US Consumer Staples stocks, 20 rose and 28 fell today. Notable movers include COCO at USD 58.11 with a 1-day change of +1.49% and a typical hold time of 11 days, BTI at USD 53.82 down 1.07% with 100% buy order activity and a typical hold time of 86 days, and DNUT at USD 2.90 up 1.05% with 100% sell order activity and a typical hold time of 45 days.

More News

Microsoft stock grew 14-fold since 2014 under Nadella, but heavy AI spending raises questions on future growth.

Microsoft stock grew 14-fold since 2014 under Nadella, but heavy AI spending raises questions on future growth.

Since Satya Nadella became CEO in 2014, Microsoft stock has increased roughly 14 times, delivering an annual growth rate of 23%. This remarkable turnaround ended 14 years of negative growth for the company. However, with Microsoft now investing heavi...

Market News
Neutral
2 hours ago
Lakewood-Amedex CEO to present new antimicrobial data at three major biotech conferences in October

Lakewood-Amedex CEO to present new antimicrobial data at three major biotech conferences in October

Lakewood-Amedex Biotherapeutics announced that CEO Kelvin Cooper, Ph.D., will participate in three key industry events in October 2026, including the Maxim Growth Summit, ThinkEquity Conference, and IDWeek. At these events, Dr. Cooper will present da...

Market News
Neutral
4 hours ago
Kyndryl opens AI Innovation Lab in Dallas, creating 300 jobs and boosting US AI adoption.

Kyndryl opens AI Innovation Lab in Dallas, creating 300 jobs and boosting US AI adoption.

Kyndryl has launched its first U.S. AI Innovation Lab in the Dallas-Fort Worth area, aiming to create up to 300 skilled jobs in AI and technology over four years. The lab will help customers modernize technology for AI adoption using Kyndryl's Agenti...

Market News
Bullish
4 hours ago
Equinix schedules Q3 2026 earnings call for October 28 to discuss financial results.

Equinix schedules Q3 2026 earnings call for October 28 to discuss financial results.

Equinix, a global digital infrastructure company, announced its quarterly earnings call for Q3 2026 will be held on October 28, 2026, at 5:30 p.m. ET. The company will review its financial results for the period ending September 30, 2026. Investors c...

Company Fundamentals
Neutral
4 hours ago
Joby Aviation stock nears 52-week low despite progress toward commercial passenger flights and raised revenue forecast.

Joby Aviation stock nears 52-week low despite progress toward commercial passenger flights and raised revenue forecast.

Joby Aviation's stock trades near its 52-week low at $6.13 while the company advances toward its first commercial passenger flights, highlighted by a recent five-day demonstration in Dallas-Fort Worth under a federal early operations program. Despite...

Analyst Insights
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App